Abstract 111P
Background
In China, fruquintinib is approved for third-line treatment of patients with metastatic colorectal cancer(mCRC). There are no prospective randomized controlled studies comparing the efficacy of fruquintinib and fruquintinib in combination with immune checkpoint inhibitors (ICIs). In this study, we aimed to compare the efficacy and safety of fruquintinib monotherapy versus combination with ICIs in MSS mCRC.
Methods
We retrospectively analyzed mCRC patients who received fruquintinib in Sun Yat-sen University Cancer Center from January 2020 to January 2022. The primary endpoints were overall survival (OS), progression-free survival (PFS) and adverse events. The secondary endpoints were objective remission rate (ORR) and disease control rate (DCR).
Results
A total of 184 patients with mCRC were included in this study, and 61 patients received ICIs combined with fruquintinib. Most patients received second line and above treatment before the study treatment. The ORR of fruquintinib combined with ICIs group (Group A, n=61) and fruquintinib group (Group B, n=123) were 14.3% and 3.6%; the DCR were 55.1% and 39.8%, respectively. Group A had a significant longer median PFS than Group B (3.9 months vs 3.3 months, P=0.015). However, the median OS was no significant difference between the two groups (mOS: 9.3 months vs 7.9 months, P=0.414). In the third line and above, there was no statistically significant difference in OS and PFS between the two groups. Multivariate analysis showed that baseline liver metastasis and lactate dehydrogenase (LDH)of≥313.3 were associated with shorter PFS in those 184 patients. Adverse effects of two groups were generally similar (91.8% vs 93.2%, P=0.738), and the most common adverse effects of two groups were the hand–foot skin reaction, hoarseness and hypertension. The probability of treatment-related adverse events (TRAEs)of grade 3 or higher was broadly similar in both groups (14.1% vs 14.6%, P=0.916).
Conclusions
In the real world, there was no difference in OS and in the incidence of adverse events between patients with MSS mCRC patients treated with fruquintinib monotherapy versus in combination with ICIs.
Clinical trial identification
NCT04005066.
Editorial acknowledgement
Legal entity responsible for the study
State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Sun Yat-sen University Cancer Center.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
16P - Patient and healthcare practitioner preferences in early-stage triple-negative breast cancer treatment: A discrete choice experiment
Presenter: Jiun-I Lai
Session: Poster Display
Resources:
Abstract
17P - Initial outcomes of the ACT Now PRIME CARE for breast cancer: Prevention of Breast canceR (screening/ stage shifting) utilizing Integrated MobilE Clinics and pAtient Reported online Evaluations and Education
Presenter: Herdee Gloriane Luna
Session: Poster Display
Resources:
Abstract
18P - Optimizing premenopausal HR+ HER2–ve eBC management in India: Insights from expert consensus
Presenter: Anitha Ramesh
Session: Poster Display
Resources:
Abstract
19P - Referral patterns among breast cancer patients in county-level hospitals in China
Presenter: Ping Lu
Session: Poster Display
Resources:
Abstract
20P - Real-world treatment of HER2+ and HR+/HER2- early breast cancer in county areas of China
Presenter: Ping Lu
Session: Poster Display
Resources:
Abstract
21P - Duration of breast cancer trials: Analysis of predicted versus actual completion date
Presenter: Daniëlle Verschoor
Session: Poster Display
Resources:
Abstract
22P - Impact of an online Asian genetic risk calculator on risk perception: Cancer-related distress and uptake of genetic counselling among Malaysian breast cancer patients (The ARiCa Study)
Presenter: HEAMANTHAA Padmanabhan
Session: Poster Display
Resources:
Abstract
23P - Consensus statements and expert recommendations for BRCAm breast cancer in the Asia-Pacific region (STREAM-AP)
Presenter: Soo Chin Lee
Session: Poster Display
Resources:
Abstract
24P - Germline genetic testing for hereditary cancer: A retrospective analysis in a single site referral centre in Malaysia
Presenter: Vivian Lee
Session: Poster Display
Resources:
Abstract
25P - Clinical presentations and prognostication of HER2-low breast cancer in Taiwan
Presenter: Bo-Fang Chen
Session: Poster Display
Resources:
Abstract